Skip to content
Search

Latest Stories

Pharmacy First threshold increase: Community Pharmacy England urges Ministers to act

Pharmacy First threshold increase: Community Pharmacy England urges Ministers to act

Community pharmacies cannot afford to lose out on this monthly Pharmacy First payment amidst a funding crisis - Janet Morrison 

Community Pharmacy England (CPE) has voiced concerns that pharmacy owners may find it challenging to achieve the increased Pharmacy First thresholds planned for September and October.

Following initial representations by CPE, Ministers agreed to temporarily reduce the threshold to 15 for August.


However, with no further updates since, the Pharmacy First threshold is set to rise to 20 clinical pathway consultations in September.

Janet Morrison, Chief Executive of Community Pharmacy England, expressed her concerns, stating: “The ability of pharmacy owners to meet the Pharmacy First monthly payment thresholds is a major ongoing concern, and the latest data highlights this burning issue.”

Janet noted that although the August adjustment provided some relief, Ministers must urgently take further action to support pharmacies through the planned increase in thresholds for September and October.

“Amidst a funding crisis, community pharmacies cannot afford to lose out on this vital payment,” she said.

Morrison stressed that community pharmacy has upheld its end of the agreement in launching the Pharmacy First service.

She called on NHS England to match this commitment with “more effective advertising and ensuring that GPs refer as many patients as possible.”

“We remain determined to push for full commitment on all sides to the shared objective of making the service a success, mindful that it is critical to the Government’s manifesto commitment to build on the service to create a wider Community Pharmacist Prescribing Service,” Janet added.

The CPE Committee recently conducted an opinion poll, inviting pharmacy owners to provide their insights and views on the rising Pharmacy First thresholds.

This feedback will be reviewed at the upcoming Community Pharmacy England Committee meeting in September.

Launched on January 31, 2024, the Pharmacy First service allows community pharmacies to offer advice to patients and supply NHS medicines (where clinically appropriate) to treat seven common health conditions without a prescription from a GP.

The seven conditions include earache, sore throat, sinusitis, impetigo, infected insect bites, shingles and urinary tract infections.

According to data from the NHS Business Services Authority (NHSBSA), from 31 January to 30 April 2024, over 9,976 community pharmacies delivered and claimed over 423,000 Pharmacy First clinical pathway consultations.

Of these consultations, 78 per cent resulted in a medicine being supplied to patients.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less